Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Vaccination with dendritic cells (DCs), the most potent professional antigen-presenting cells in the body, is a promising approach in cancer immunotherapy. However, tumors induce immunosuppression in their microenvironment that suppresses and impairs the function of DCs. Therefore, human clinical tr...

Full description

Bibliographic Details
Main Authors: Sadia Zafar, Suvi Parviainen, Mikko Siurala, Otto Hemminki, Riikka Havunen, Siri Tähtinen, Simona Bramante, Lotta Vassilev, Hongjie Wang, Andre Lieber, Silvio Hemmi, Tanja de Gruijl, Anna Kanerva, Akseli Hemminki
Format: Article
Language:English
Published: Taylor & Francis Group 2017-02-01
Series:OncoImmunology
Subjects:
cd40 ligand
dendritic cells
oncolytic adenovirus
t-cells
tumor microenvironment
Online Access:http://dx.doi.org/10.1080/2162402X.2016.1265717

Internet

http://dx.doi.org/10.1080/2162402X.2016.1265717

Similar Items